Headquartered in Waltham, MA·Fiscal year ends December·NASDAQ: AKBA·akebia.com
About Akebia Therapeutics
Akebia Therapeutics is a fully integrated biopharmaceutical company focused on kidney disease. It has two commercial products.
- **Vafseo (vadadustat):** A once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for anemia due to chronic kidney disease (CKD) in adults on dialysis for at least three months. It is approved in 37 countries and is in U.S. commercial launch, with about 11,500 active patients at the end of Q3 2026.
- **Auryxia (ferric citrate):** A legacy product whose revenues are declining due to generic competition and pricing pressure.
The company also earns license, collaboration, royalty and supply revenues.
Its clinical-stage rare kidney disease pipeline includes:
- **Ebribafusp alfa:** A potential next-generation complement inhibitor in a Phase 2 basket trial in C3 glomerulopathy, lupus nephritis and IgA nephropathy.
- **Praliciguat:** In Phase 2 development for focal segmental glomerulosclerosis (FSGS).
Akebia trades on Nasdaq under the ticker AKBA. Updated
Thursday’s additional top analyst upgrades and downgrades included Advanced Micro Devices, Akebia Therapeutics, Dell Technologies, HP, Starwood Property Trust and State Street.